Private company
ChemoCentryx, Inc.
American pharmaceutical preparations company based in Mountain View.
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2021
-403.2%Operating margin3
-408.9%Net margin3
-50.3%Revenue growth, 20213
-46.0%Return on equity3
0.02×Debt to equity3
-$94.6MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2021
- Research and development50¢$83.0M
- Selling, general and admin48¢$78.9M
- Interest2¢$2.7M
Out of $32.2M in revenue.3 The company lost money this year.
Financial statements
| Fiscal year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenue | $11.9M4 | $82.5M5 | $42.9M6 | $36.1M3 | $64.9M3 | $32.2M3 | |
| Research and development | $33.2M7 | $37.9M4 | $49.5M5 | $62.7M6 | $70.3M3 | $77.9M3 | $83.0M3 |
| Selling, general and admin | $24.2M3 | $42.2M3 | $78.9M3 | ||||
| Operating income | -$47.7M7 | -$40.7M4 | $16.5M5 | -$40.3M6 | -$58.3M3 | -$55.2M3 | -$129.9M3 |
| Interest | $4.0K5 | $1.2M6 | $2.1M3 | $2.6M3 | $2.7M3 | ||
| Income tax | $07 | $04 | $05 | $06 | $03 | $03 | $03 |
| Net income | -$47.3M7 | -$40.0M4 | $17.9M5 | -$38.0M6 | -$55.5M3 | -$55.4M3 | -$131.8M3 |
| Earnings per share | -$1.087 | -$0.864 | $0.375 | -$0.765 | -$0.985 | ||
| Earnings per share (diluted) | -$1.087 | -$0.864 | $0.365 | -$0.765 | -$0.985 |
| Fiscal year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Cash | $12.8M7 | $12.0M7 | $40.0M4 | $28.1M5 | $39.2M6 | $32.3M3 | $50.0M3 |
| Current assets | $72.0M10 | $148.7M7 | $179.8M4 | $181.4M5 | $174.4M6 | $441.6M3 | $269.2M3 |
| Total assets | $78.2M10 | $155.9M7 | $189.3M4 | $183.3M5 | $209.1M6 | $518.9M3 | $425.7M3 |
| Current liabilities | $5.5M10 | $38.3M7 | $32.9M4 | $64.4M5 | $59.1M6 | $51.6M3 | $63.0M3 |
| Long-term debt | $4.7M4 | $19.7M5 | $19.8M6 | $18.1M3 | $4.7M3 | ||
| Total liabilities | $5.6M10 | $106.0M7 | $110.1M4 | $168.6M5 | $143.1M6 | $133.3M3 | $139.5M3 |
| Shareholders’ equity | $72.5M4 | $49.9M5 | $79.3M6 | $14.7M3 | $66.0M3 | $385.6M3 | $286.1M3 |
| Shares outstanding | 44.2M shares10 | 48.1M shares7 | 48.8M shares4 | 50.7M shares5 | 60.2M shares6 | 69.5M shares3 | 70.4M shares3 |
Leadership
Who has led ChemoCentryx, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
201520202025
- Chief executive officerThomas J. Schall Feb 8, 2012 to Oct 24, 202211
- PresidentThomas J. Schall Feb 8, 2012 to Oct 24, 202211
- Chief financial officerSusan M. Kanaya Feb 8, 2012 to Aug 18, 202212
- Chief operating officerTausif Butt Feb 24, 2021 to Oct 24, 202213
- Chief operating officerWilliam Fairey Jan 5, 2018 to Jan 5, 201814
Board members and other officers (22)
- SVP, Finance & Acctg OfficerYi Ching Yau Jun 8, 2022 to Jun 8, 202215
- OfficerSusan M. Kanaya Oct 24, 2022 to Oct 24, 202216
- EVP, Chief Medical OfficerRita Jain Oct 7, 2021 to Oct 24, 202217
- Principal Acctg OfficerPui San Kwan Mar 7, 2018 to Mar 1, 202118
- EVP, Chief of Strategic Dev.Anne-Marie Duliege Mar 28, 2014 to Nov 20, 201419
- SVP, ResearchIsrael Charo Sep 22, 2014 to Sep 22, 201420
- SVP, Drug Discovery & CSOJuan C. Jaen Feb 8, 2012 to Jul 26, 201321
- CBO and TreasurerMarkus J. Cappel Feb 8, 2012 to Oct 24, 202222
- SVP of Med & Clinical AffairsPetrus Bekker Feb 8, 2012 to Jul 13, 201723
- Board memberSusan M. Kanaya Jan 4, 2022 to Oct 24, 202224
- Board memberDavid E. Wheadon May 31, 2022 to Oct 24, 202225
- Board memberJennifer Lyn Herron Jun 30, 2022 to Oct 24, 202226
- Board memberRita Jain Mar 29, 2019 to Oct 24, 202227
- Board memberHenry A. McKinnell Oct 19, 2016 to May 24, 202228
- Board memberThomas A. Edwards Jul 30, 2015 to Oct 24, 202229
- Board memberIra Klein May 28, 2013 to May 26, 201530
- Board memberEdward Penhoet Feb 8, 2012 to May 24, 201331
- Board memberRishi Gupta Feb 8, 2012 to Jun 26, 201232
- Board memberRoger C. Lucas Feb 8, 2012 to Mar 8, 201933
- Board memberThomas J. Schall Feb 8, 2012 to Oct 24, 202211
- Board memberJoseph M. Feczko Apr 27, 2012 to Oct 24, 202234
- Board memberJames L. Tyree Jun 7, 2012 to Oct 24, 202235
Timeline
- Feb 8, 2012New chief executive Thomas J. Schall becomes CEO11
Filings
88 filings to the SEC since October 2021: 1 annual reports, 3 quarterly reports, 15 major events, 46 insider forms, 7 large holders, 16 other. The latest 20:
- Oct 31, 202215-12G EDGAR
- Oct 24, 20224 FORM 4 SUBMISSION EDGAR
- Oct 24, 20224 FORM 4 SUBMISSION EDGAR
- Oct 24, 20224 FORM 4 SUBMISSION EDGAR
- Oct 24, 20224 FORM 4 SUBMISSION EDGAR
- Oct 24, 20224 FORM 4 SUBMISSION EDGAR
- Oct 24, 20224 FORM 4 SUBMISSION EDGAR
- Oct 24, 20224 FORM 4 SUBMISSION EDGAR
- Oct 24, 20224 FORM 4 SUBMISSION EDGAR
- Oct 24, 20224 FORM 4 SUBMISSION EDGAR
- Oct 24, 20224 FORM 4 SUBMISSION EDGAR
- Oct 24, 20224 FORM 4 SUBMISSION EDGAR
- Oct 20, 202225-NSE EDGAR
- Oct 20, 2022S-8 POS EDGAR
- Oct 20, 2022S-8 POS EDGAR
- Oct 20, 2022POSASR EDGAR
- Oct 20, 20228-K EDGAR
- Oct 18, 20228-K EDGAR
- Oct 7, 2022DEFA14A EDGAR
- Sep 20, 2022DEFA14A EDGAR
The 88 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 7 such filings since October 2021:
- Sep 12, 2022SC 13G/A
- Feb 14, 2022SC 13G/A
- Feb 14, 2022SC 13G/A
- Feb 9, 2022SC 13G/A
- Feb 9, 2022SC 13G/A
- Feb 3, 2022SC 13G/A
- Oct 14, 2021SC 13D/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARTausif Butt, Chief operating officer
- 14
- 15
- 16SEC EDGARSusan M. Kanaya, Officer
- 17
- 18
- 19
- 20SEC EDGARIsrael Charo, SVP, Research
- 21
- 22SEC EDGARMarkus J. Cappel, CBO and Treasurer
- 23
- 24SEC EDGARSusan M. Kanaya, Board member
- 25SEC EDGARDavid E. Wheadon, Board member
- 26SEC EDGARJennifer Lyn Herron, Board member
- 27SEC EDGARRita Jain, Board member
- 28SEC EDGARHenry A. McKinnell, Board member
- 29SEC EDGARThomas A. Edwards, Board member
- 30SEC EDGARIra Klein, Board member
- 31SEC EDGAREdward Penhoet, Board member
- 32SEC EDGARRishi Gupta, Board member
- 33SEC EDGARRoger C. Lucas, Board member
- 34SEC EDGARJoseph M. Feczko, Board member
- 35SEC EDGARJames L. Tyree, Board member